Alkem’s Occlutech deal adds ₹140.79 crore MedTech revenue

Alkem Laboratories Limited created a reportable MedTech segment after acquiring 55% of Occlutech Holding AG on 16 July 2026, generating ₹140.79 crore of revenue and a ₹61.88 crore segment loss in the six months ended 30 September 2026. Occlutech was consolidated only from the acquisition date, limiting comparison with earlier periods.

What did Alkem acquire from Occlutech?

Alkem acquired a 55% equity stake in Occlutech through its wholly owned subsidiary, Alkem Medtech Private Limited, completing the purchase of a controlling interest on 16 July 2026. The fair-value consideration was ₹1,079.76 crore, consisting of ₹877.83 crore in cash consideration and ₹201.93 crore in deferred consideration, subject to adjustments under the share purchase agreement.

Occlutech became a subsidiary from the acquisition date, and Alkem consolidated its financial results from 16 July rather than for the full quarter ended 30 September 2026. Alkem said the timing means current-period consolidated results are not comparable with the corresponding prior periods, although it recast prior segment data under the revised Pharmaceuticals, Biotech and MedTech structure.

The transaction was accounted for under Indian Accounting Standard 103, or Ind AS 103, on business combinations. Under the provisional purchase price allocation, Alkem identified acquired assets of ₹1,604.78 crore and liabilities of ₹920.86 crore, including a deferred-tax liability of ₹172.40 crore, and recognised goodwill of ₹703.60 crore.

How did Occlutech change Alkem’s segment reporting?

Occlutech’s acquisition led Alkem to identify MedTech as a separate reportable operating segment alongside Pharmaceuticals and Biotech. The group reassessed its segments after the July 2026 deal because the information reviewed by the chief operating decision maker, or CODM, had changed.

MedTech revenue rose to ₹133.14 crore in the quarter ended 30 September 2026 from ₹7.65 crore in the quarter ended 30 June 2026 and ₹27.00 crore in the quarter ended 30 September 2025. In the latest quarter, Pharmaceuticals recorded revenue of ₹4,347.92 crore, while Biotech recorded ₹129.79 crore, showing that Pharmaceuticals remained the dominant operating segment.

Alkem manages treasury operations centrally, so cash balances, bank deposits, investments, borrowings and the associated income and expense are reported as unallocated rather than assigned to MedTech. Tax assets and tax liabilities are also unallocated, meaning segment results are measured before interest, unallocable income, exceptional items and tax.

What did Alkem’s MedTech segment report after the deal?

Alkem’s MedTech segment reported ₹133.14 crore of revenue and a ₹49.63 crore segment loss in the quarter ended 30 September 2026. For the six months ended 30 September 2026, MedTech revenue was ₹140.79 crore and its segment loss was ₹61.88 crore, indicating that nearly all of the reported six-month contribution came after the 16 July acquisition.

The MedTech loss was ₹12.25 crore in the June 2026 quarter and ₹6.31 crore in the September 2025 quarter, based on the recast segment presentation. These figures do not provide a like-for-like operating comparison because Occlutech’s results entered the consolidated accounts only from 16 July 2026.

Consolidated revenue from operations reached ₹4,551.99 crore in the September 2026 quarter, compared with ₹3,740.15 crore in the June 2026 quarter and ₹4,000.99 crore in the September 2025 quarter. Consolidated profit for the period was ₹667.13 crore, against ₹520.98 crore in the preceding quarter and ₹779.11 crore a year earlier.

The latest quarterly segment results show a contrast between the businesses: Pharmaceuticals generated ₹1,051.88 crore, while Biotech lost ₹114.14 crore and MedTech lost ₹49.63 crore. Total segment profit before interest, unallocable income, exceptional items and tax was ₹888.11 crore, up from ₹827.16 crore in the September 2025 quarter.

How did the acquisition change Alkem’s assets and liabilities?

Alkem’s MedTech segment assets rose to ₹2,486.34 crore at 30 September 2026 from ₹39.12 crore at 30 June 2026 and ₹37.55 crore at 31 March 2026. The increase coincided with Occlutech’s consolidation and the recognition of acquired assets, liabilities and transaction-related goodwill under the provisional purchase price allocation.

Consolidated goodwill increased to ₹1,221.02 crore at 30 September 2026 from ₹523.64 crore at 31 March 2026. Other intangible assets rose to ₹1,360.76 crore from ₹256.76 crore, while total non-current assets increased to ₹10,077.50 crore from ₹8,662.45 crore over the same period.

MedTech segment liabilities reached ₹333.07 crore at 30 September 2026, compared with ₹56.85 crore at 30 June 2026 and ₹72.90 crore at 31 March 2026. At group level, non-current borrowings rose to ₹1,033.46 crore from ₹492.45 crore, and deferred-tax liabilities increased to ₹203.39 crore from ₹15.12 crore.

Alkem’s cash-flow statement recorded ₹808.04 crore of purchase consideration for acquisition of business, net of acquired cash and cash equivalents, in the six months ended 30 September 2026. That cash-flow amount differs from the ₹1,079.76 crore fair-value consideration disclosed for Occlutech, which includes ₹201.93 crore of deferred consideration.

Conclusion

The July 2026 deal changed Alkem’s reporting structure as well as its balance sheet. MedTech contributed ₹140.79 crore of revenue and a ₹61.88 crore loss in the six months ended 30 September 2026, while its assets increased to ₹2,486.34 crore and consolidated goodwill rose by ₹697.38 crore from 31 March 2026.

The next disclosed item to watch is finalisation of the provisional purchase price allocation within the measurement period permitted under Ind AS 103. Alkem said any resulting changes will be recognised retrospectively from 16 July 2026, which could revise goodwill, acquired identifiable assets or assumed liabilities.